WHO’s role in the global health system (original) (raw)
Research and development Pharmaceuticals Access to medicines Intellectual property WHO reform Consultative Expert Working Group on R&D (CEWG) R&D treaty Neglected diseases Antibiotics a b s t r a c t Recent global debates on the research and development (R&D) of health technologies, such as drugs, diagnostics and vaccines, can be seen as a microcosm of discussions on the role of the World Health Organization (WHO) in the global health system more broadly. The global R&D system has come under heightened scrutiny with the publication of a 2012 report by the WHO Consultative Expert Working Group on Research and Development (CEWG), which made a number of recommendations to more equitably meet global health needs. The CEWG report followed a decade-long process of debate at the WHO on the weaknesses of the global R&D system, which include problems of affordability, limited research where market returns are small or uncertain (such as the 'neglected diseases' that predominantly affect the world's poorest), inefficient overlap of research efforts, and overuse of medicines such as antibiotics. The CEWG report called on WHO Member States to develop a global framework to improve monitoring, coordination and financing of R&D efforts through the establishment of a Global Health R&D Observatory and the negotiation of a binding treaty on R&D. While the treaty option has been put on the back-burner for several years, Member States nevertheless agreed at the 2013 World Health Assembly (WHA) on concrete steps towards a global framework. Progress at the 2013 WHA reaffirmed the central role of WHO as a convener, and the WHA's decision to create the Observatory within the WHO Secretariat underscored the organization's role as a source of strategic knowledge in the global health system. However, despite WHO's constitutional mandate as
Sign up for access to the world's latest research
checkGet notified about relevant papers
checkSave papers to use in your research
checkJoin the discussion with peers
checkTrack your impact
Related papers
Health research policy and systems / BioMed Central, 2015
In May 2013, WHO's Member States requested the WHO to establish a Global Observatory on Health Research and Development (R&D), as part of a strategic work-plan to promote innovation, build capacity, improve access and mobilize resources to address diseases that disproportionately affect the world's poorest countries.The rationale for establishing a Global Observatory on Health R&D is to provide a mechanism to monitor and analyse health R&D resource flows, product pipelines and research outputs, with a view to contributing to the identification of gaps to inform priority-setting for new R&D investments to be operationalised through a new global financing and coordination mechanism for health R&D and utilized by all stakeholders informing health research policy decisions in countries, civil society and the private sector.As one of the mechanisms to achieve the goals of the Global Observatory on Health R&D, WHO is launching a Call for Papers to be published as a Thematic Series...
Global rules for global health: why we need an independent, impartial WHO
BMJ (Clinical research ed.), 2014
Recent outbreaks of MERS highlight the need for a global response to infectious disease WHO has had a crucial role in developing rapid information sharing on new infectious threats and fair arrangements for access to drugs and vaccines and to research and development WHO is the only international agency that can broker such global rules but is badly underfunded to perform this core function The MERS outbreaks offer an opportunity to reform WHO financing
This paper links the main issues of the project “Contested World Order” (WZB, GIGA, HSFK) to the policy field of global health: the authority of the institutional setting, and the preferences and strategies of rising powers and non-state actors (NStAs) – the assumed protagonists of recent power shifts. The first part discusses the loss of WHO authority since the rise of Global Health Governance, and WHO’s fight to reassert its position. The core of the paper deals with the conflict on intellectual property rights (IPRs) and access to medicines as a central issue in global health. Between 1995 and 2005, civil society organizations (CSOs) and some emerging powers fought successfully for improving access conditions under the TRIPS agreement (Doha Declaration). WHO’s activities to regain the initiative led to the adoption of the Global Strategy and Plan of Action on Public Health, Innovation and Intellectual Property (2008) (GSPoA). Chapter 4 analyses the role of NStAs and rising powers (notably BRICS) during negotiations on implementing GSPoA. While CSOs insisted on a binding R&D treaty, BRICS countries finally agreed to more modest results. They support the welfare-orientation and the intergovernmental character of WHO but without seriously challenging basic rules in the global economy. Finally, consensus within WHO was restraint to issues which did not touch the basic IPR framework.
Global Governance for Facilitating Access to Medicines: Role of World Health Organization
2013
Growing dissatisfaction with constant interference of trade regime with basic human right to health has necessitated the search for an alternative forum competent to take lead in the struggle for global access to affordable medicines, and thus it ended up with the World Health Organization. The WHO, in turn, recommended a Global Health R&D Treaty. Nevertheless, the clash between global health actors and the industry continues, occasionally affecting the WHO initiatives. Still, there is a room for hope.
Loading Preview
Sorry, preview is currently unavailable. You can download the paper by clicking the button above.